Content about Bisphosphonates

January 15, 2014

Nearly three-quarters of osteoporosis patients prefer to take their medication in a form other than an oral solid, according to a new survey.

SAN ANTONIO — Nearly three-quarters of osteoporosis patients prefer to take their medication in a form other than an oral solid, according to a new survey.

April 4, 2013

Dr. Reddy's Labs has launched zoledronic acid injection in the 5 mg-per-100-mL strength, the Indian generic drug maker Thursday.

HYDERABAD, India — Dr. Reddy's Labs has launched zoledronic acid injection in the 5 mg-per-100-mL strength, the Indian generic drug maker Thursday.

The drug, launched following its approval by the Food and Drug Administration, is a generic version of Novartis' Reclast and is used to treat osteoporosis. Reclast had sales of $355 million during the 12-month period that ended in February, according to IMS Health.

August 7, 2012

A biotech drug made by Eli Lilly for osteoporosis appeared no more or less effective than a pharmaceutical drug available as a generic in treating women with related bone fractures, but was more effective in some other measures, according to results of a late-stage clinical trial released Tuesday.

INDIANAPOLIS — A biotech drug made by Eli Lilly for osteoporosis appeared no more or less effective than a pharmaceutical drug available as a generic in treating women with related bone fractures, but was more effective in some other measures, according to results of a late-stage clinical trial released Tuesday.

July 2, 2012

Dr. Reddy's has launched a drug designed to prevent and treat osteoporosis.

HYDERABAD, India — Dr. Reddy's has launched a drug designed to prevent and treat osteoporosis.

The generic drug maker launched ibandronate sodium tablets in the 150-mg strength, following approval by the Food and Drug Administration for the drug maker's abbreviated new drug application. The drug is a generic version of Boniva.

The branded drug and generic versions had U.S. sales of approximately $486 million during the 12-month period ended in March, according to IMS Health.

April 17, 2012

A U.S. drug maker has made a deal with a Swiss company to manufacture and sell a new osteoporosis treatment in North America.

SAN ANTONIO — A U.S. drug maker has made a deal with a Swiss company to manufacture and sell a new osteoporosis treatment in North America.

Mission Pharmacal announced Tuesday a patent and technology licensing agreement with Freienbach, Switzerland-based EffRx Pharmaceuticals for Binosto (alendronate sodium) effervescent tablets in the United States and Canada. Financial terms were not disclosed.

March 21, 2012

The Food and Drug Administration has approved Watson's generic version of a drug used to prevent and treat osteoporosis in post-menopausal women, the company said.

PARSIPPANY, N.J. — The Food and Drug Administration has approved Watson's generic version of a drug used to prevent and treat osteoporosis in post-menopausal women, the company said.

Watson announced the FDA's approval of ibandronate tablets in the 150-mg strength, a generic version of Genentech's Boniva. Watson plans to launch its version in second quarter 2012.

March 19, 2012

The Food and Drug Administration has approved the first generic version of a drug for treating and preventing osteoporosis in women after menopause, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved the first generic version of a drug for treating and preventing osteoporosis in women after menopause, the agency said Monday.

The FDA announced the approval of ibandronate tablets in the 150-mg strength made by Apotex, Orchid Healthcare and Mylan Pharmaceuticals. Genentech makes the branded version of the drug.

March 15, 2012

The Food and Drug Administration approved an effervescent tablet for treating osteoporosis.

FREIENBACH, Switzerland — The Food and Drug Administration approved an effervescent tablet for treating osteoporosis.

EffRx Pharmaceuticals announced the FDA approval of Binosto (alendronate sodium), a strawberry-flavored tablet designed to dissolve in water that the company called the first treatment of its kind. The drug is designed to treat osteoporosis in menopausal women and increase bone mass in men with osteoporosis. EffRx expects to launch Binosto in third quarter 2012.

November 18, 2010

The Food and Drug Administration has approved a treatment for preventing skeletal injuries in patients...

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for preventing skeletal injuries in patients whose cancer has spread to the bone.

 

The FDA announced Friday the approval of Thousand Oaks, Calif.-based biotech company Amgen’s Xgeva (denosumab) for bone metastases.

 

 

October 11, 2010

The Food and Drug Administration has approved a new formulation of a drug for osteoporosis...

ARDEE, Ireland The Food and Drug Administration has approved a new formulation of a drug for osteoporosis made by Warner Chilcott, the drug maker said Monday.

 

Warner Chilcott announced the approval of Atelvia (risendronate sodium), a treatment for postmenopausal osteoporosis, which it plans to launch early next year. The drug is a delayed-release formulation of Actonel.

 

 

March 11, 2010

Analysis by the Food and Drug Administration has yet to establish a link between thigh-bone...

January 28, 2010

The Food and Drug Administration has given tentative approval to a generic version of a...